89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022 SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data in non-alcoholic steatohepatitis (NASH) will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, to be held in London, UK on June 22-26, 2022. Presentation details are as follows:
Abstract Title: Pegozafermin Led to Improved Liver Histology, Liver-related Non-invasive Tests and Metabolic Profile, With Favorable Safety and Tolerability, in an Open-label Cohort of a Phase 1b/2a Study in Subjects With Non-alcoholic Steatohepatitis Format: Poster presentation (#SAT-139)
Presentation Date and Time: Saturday, June 25th 9:00 – 18:30 BST
Format: Poster presentation (#SAT-143)
Presenting Author: Naim Alkhouri, MD, Chief of Transplant Hepatology and Director of the Fatty Liver Program, Arizona Liver Health (ALH)
Presentation Date and Time: Saturday, June 25th 9:00 – 18:30 BST
Format: Poster presentation (#SAT-131)
Presenting Author: Naim Alkhouri, MD, Chief of Transplant Hepatology and Director of the Fatty Liver Program, Arizona Liver Health (ALH)
Presentation Date and Time: Saturday, June 25th 9:00 – 18:30 BST